Transcription factor Meis1 act as a new regulator of ischemic arrhythmias in mice

Yining Liu a,1, Jiamin Lia,1, Ning Xu a, Hang Yu a, Liling Gong a, Qingsui Li a, Zhenyu Yang a, Sijia Li a, Jiming Yang a, Di Huang a, Yadong Xue a, Genlong Xue a, Jiali Liu a, Haixin Chen a, Ruijie Zhang a, Anqi Li a, Yiming Zhao a, PengYu Li a, Ming Li a, Mingbin Liu a, Ning Wang a, b, *, Benzhi Cai a, b, *

a Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China

b Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University (Institute of Clinical Pharmacy, The University Key Laboratory of Drug Research, Heilongjiang Higher Education Institutions), Harbin, China

Highlights

- The reduction of Meis1 after MI leads to an increased susceptibility to arrhythmia.
- Meis1 deficiency is related to ubiquitination proteasome pathway mediated by CDC20.
- Meis1 acts as a new transcription activator for SCN5A in cardiomyocytes.
- After Meis1 recovery, the electrophysiological function in cardiomyocytes are improved.
- Meis1 is a new target for the treatment of arrhythmia after myocardial infarction.

Graphical Abstract

ABSTRACT

Introduction: The principal voltage-gated Na+ channel, NaV1.5 governs heart excitability and conduction. NaV1.5 dysregulation is responsible for ventricular arrhythmias and subsequent sudden cardiac death (SCD) in post-infarct hearts. The transcription factor Meis1 performs a significant role in determining differentiation fate and regenerative capability of cardiomyocytes. However, the functions of Meis1 in ischemic arrhythmias following myocardial infarction (MI) are still largely undefined.

Objectives: Here we aimed to study whether Meis1 could act as a key regulator to mediate cardiac Na+ channel and its underlying mechanisms.

Methods: Heart-specific Meis1 overexpression was established by AAV9 virus injection in C57BL/6 mice. The QRS duration, the incidence of ventricular arrhythmias and cardiac conduction velocity were evaluated by ECG, programmed electrical stimulation and optical mapping techniques respectively. The conventional patch clamp technique was performed to explore the I Na characteristics of isolated mouse ventricular myocytes. In vitro, Meis1 was also overexpressed in hypoxic-treated neonatal cardiomyocytes.

ARTICLE INFO

Article history:
Received 29 August 2021
Revised 25 October 2021
Accepted 10 November 2021
Available online 15 November 2021

Keywords:
Meis1
Ventricular arrhythmias
Myocardial infarction
NaV1.5 channel
CDC20
Ubiquitin

Peer review under responsibility of Cairo University.
* Corresponding authors at: Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China (N. Wang).
E-mail addresses: wangning@ems.hrbmu.edu.cn (N. Wang), caibz@ems.hrbmu.edu.cn (B. Cai).
1 The first two authors contributed equally to this work.

https://doi.org/10.1016/j.jare.2021.11.004
2090-1232/© 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Ventricular arrhythmias represent one of the leading causes of morbidity and mortality in patients with acute myocardial infarction (AMI) [1]. The survivors of AMI still have an increased risk of ventricular arrhythmias and sudden cardiac death, mainly due to ion channels remodeling and cardiac electrical abnormalities in MI [2]. Although traditional antiarrhythmic drugs are capable to alleviate arrhythmias to a certain extent, their negative inotropic and arrhythmogenic effects cannot be ignored [3]. Voltage-gated cardiac Na⁺ current (I₅Na) carried by the SCN5A-encoded Naᵥ1.5 α subunit acts a pivotal part in the electrical conduction and excitability of the heart by regulating the depolarization process of cardiac action potential (AP) [4–5]. The dysfunction of intracellular Na⁺ channels has been shown to be a critical predisposing factor for life-threatening ventricular arrhythmias [6–8]. It was reported that the functional impairment or down-regulation of Naᵥ1.5 could slow down the conduction velocity of the infarcted heart, which was related to the death in heart failure and cardiomyopathies [9–10]. In addition, genetic analysis revealed that mutations of SCN5A are associated with multiple arrhythmogenic diseases such as Brugada syndrome and Long QT syndrome [11]. However, at present, our understanding of molecular mechanisms of cardiac Na⁺ channel dysfunction after MI is still inadequate. To define the potential mechanism of cardiac Na⁺ channel dysfunction after MI is of great significance for the therapy of post-infarcted arrhythmias.

The transcription factor Meis1 is a member of the homeobox gene family, and has emerged as a key regulator of a wide range of biological activities including cell cycle, oxidative stress, differentiation and embryonic development [12–15]. In hearts, Meis1 level was altered in postnatal and post-infarcted hearts, which has been shown to cause the loss of cardiac regenerative ability in mice [14,16]. Notably, A recent study found that the loss of transcription factor Meis1 increases the sensitivity to sudden cardiac death by inhibiting the sympathetic neurons target-field innervation [17]. In addition, two large-scale genomic association studies showed that gene mutation in Meis1 is correlated with abnormal PR interval in patients [18–19]. It has been well documented that prolongation of the PR interval is a significant indication of atrial and atrioventricular nodal conduction block in patients [20]. It suggests that Meis1 might be involved in the regulation of cardiac conduction and heart rhythm. However, whether Meis1 performs a regulatory part in cardiac Na⁺ channel and thus participates in the occurrence of arrhythmias after MI has not elucidated yet.

Accumulating evidence indicated that the post-translational modification of ubiquitin proteasome system (UPS) is largely responsible for protein degradation [21]. Recent studies have shown that the dysfunction of UPS is recognition as a potentially important mechanism involved in the onset and development of various cardiac diseases [22–23]. In the process of ubiquitin proteasome, E3 ligase as a key enzyme, specifically recognizes ubiquitinated protein substrates. Cell division cycle 20 homologue (CDC20) performs an essential role in the progression of the cell cycle via activating the anaphase promoting complex (APC). E3 ubiquitin ligase which causes the ubiquitination and degradation of specific substrates [24–25]. Recently, it was reported that CDC20 mediates PPM1K regulation of Meis1 in hematopoiesis of specific substrates [24–25]. Recently, it was reported that CDC20 mediates PPM1K regulation of Meis1 in hematopoiesis and leukemogenesis [26]. Additionally, database analysis studies have found that CDC20 was significantly enriched in rat cardiomyocytes after myocardial infarction, which indicates that CDC20 might participate in the development of myocardial ischemia [27]. However, whether CDC20 also plays a vital role on Meis1 during the course of ischemic arrhythmia and its molecular mechanism need to be further identified.

Although previous studies afforded growing evidences to support the role of sodium channel in the progress of ischemic arrhythmias caused by MI, the role of ubiquitin proteasome system and transcription factors in cardiac electrical remodeling after MI...
are still missing. Therefore, we conducted the present study to investigate the regulatory roles of Meis1 in cardiac electrical conduction and arrhythmias in the mouse MI model and elucidate its underlying mechanisms. Our results firstly showed that Meis1 acts as a transcription activator for SCN5A and prevent the Na\textsubscript{v}1.5 down regulation from MI injury. The reduction of Meis1 after MI leads to an increased susceptibility to arrhythmia, and this deficiency is associated with ubiquitination proteasome degradation.

**Materials and methods**

**Ethics statement**

All animal experiments were conducted in accordance with the NIH guidelines (Guide for the care and use of laboratory animals, NIH Publication No. 85-23, revised 1996) and the whole experimental process were carried out according to the procedures approved by the Institutional Animal Care and Use Committee of Harbin Medical University.

**AAV9-GFP construction and tail vein injection**

Recombinant adeno-associated virus serotype 9 (AAV9) vectors carrying the cardiac troponinI (cTNT) promoter driving the expression of enhanced green fluorescent protein (AAV9-cTNT-GFP) and Meis1 (AAV9-cTNT-GFP-Meis1) were provided by Hanbio Biotechnology Co., Ltd (Shanghai, China). The backbone vector AAV9-cTNT-GFP was used as a control (AAV9-NC). AAV9-cTNT-GFP-Meis1 (AAV9-Meis1), which can drive strong, cardiomyocyte-selective expression of Meis1 were injected into the tail vein at a dose of 1.3 × 10\textsuperscript{11} viral genomes (vg) per animal. Four weeks after carrier administration, the mice hearts were subjected to cryosection and then fluorescence microscopy was used for GFP distribution detection. In addition, AAV9-shMeis1/NC were administered to mice using the same method and dose as above to construct Meis1 knockdown in cardiomyocytes.

**Animal models**

Male C57BL/6 mice (20–25 g) were maintained on a 12 h light/-dark cycle at 22 °C and 55–60% humidity. The animals were randomized into the following three groups: sham, MI + AAV9-NC and MI + AAV9-Meis1 group. The left anterior descending branch of the mouse coronary artery was ligated to construct a model of myocardial infarction, which was consistent with the previous procedure [28]. In brief, mice were anesthetized in the gas chamber with 2–4% isoflurane (MIDMARK, USA) by 1000 frames per second and 100×100 pixels. ScMedia customized software (SciMedia, Costa Mesa, CA) was used to initiate fluorescence signal recording and statistics of cardiac conduction velocity.

**Patch clamp recordings**

Sodium currents in mice ventricular myocardium was recorded with whole-cell patch clamp recording technique as described previously [9,29]. All whole-cell patch-clamp recordings were conducted at room temperature (23 ± 1 °C) using a patch clamp amplifier (MultiClamp 700B; Axon Instruments Inc., Foster City, CA, USA). The ionic currents were measured in the voltage-clamp mode and the electrode resistance was 2–4 MΩ. The isolated ventricular myocyte suspension was added to the bath placed in an inverted microscope (IX-70; Olympus) and then Tyrode solution was injected. The Tyrode solution for intracardiac electromyograms were recorded and analyzed with the LabChat throughout the experiment. Ventricular fibrillation was characterized by five or more consecutive irregular fluctuations.

**Electrocardiogram**

The recording of surface standard lead II electrocardiogram (ECG) in mice of each group was performed on the biometric signal acquisition and analysis system (BL-420S, Chengdu Taimeng, China) with bipolar limb leads. Briefly, after the mice were anesthetized, two electrodes were inserted under the surface of the limbs, and then were connected to the electrocardiograph. The signals were recorded for 15 min at a frequency response of 0.05–500 Hz, followed by digitally analyzed in the BL-420S system.
NaF (adjust the pH to 7.20 with CsOH). The data were acquired and digitized by using Digidata 1440 converter (Axon Instruments Inc., Foster City, CA, USA) and pCLAMP 10.6 software (Axon Instruments Inc., Foster City, CA, USA) and stored on a computer. Data evaluation was conducted through the usage of pClampfit 10.4 software program (Axon Instruments Inc., Foster City, CA, USA).

Neonatal mouse primary cardiomyocyte culture

Neonatal primary cardiomyocytes were dissociated from 1 to 3-day-old SPF-grade mouse hearts. In brief, cardiomyocytes were isolated using a selective adherent technique after digestion with 0.25% trypsin solution. Cardiomyocytes were cultured in DMEM with 10% fetal bovine serum, 1% penicillin and streptomycin in an atmosphere of 5% CO₂ and 95% air at 37 °C for 48 h. The Meis1 plasmid, negative control (NC) was synthesized by GenePharma (Shanghai, China), which were transiently transfected using Lipofectamine2000™ transfection reagent (Invitrogen, Carlsbad, CA, USA). After 24 h of transfection, the cells were moved to an anoxic area around the infarct of the pathological mouse heart as the peri-infarcted region. After quantification with the BCA Protein Assay kit (Shanghai, China), which were transiently transfected using Lipofectamine2000™ transfection reagent (Invitrogen, Carlsbad, CA, USA), 60 μg protein from each group was fractionated by 8% SDS-PAGE and electro-blotted onto NC membranes (Pall, New York, USA). Membranes were incubated with primary antibodies overnight at 4 °C, including rabbit anti-Meis1 antibody (Abcam, UK, Cat#: ab19867, 1:1000), rabbit anti-Nav1.5 antibody (Alomame laboratory, Israel, Cat#: ASC-005, 1:200), mouse anti-CDC20 antibody (Proteintech Group, America, Cat#: 10252-1-AP, 1:500), mouse anti-UB antibody (Santa Cruz Biotechnology, Europe, Cat#: sc-8017, 1:1000), mouse anti-His antibody (Santa Cruz Biotechnology, Europe, Cat#: sc-57598, 1:200) and mouse anti-flag antibody (Sigma, USA, Cat#: F1804, 1:1000). Mouse anti-β-Actin antibody (Zhongshanjinqiao, Beijing, China, Cat#: TA-09, 1:1000) was used as an internal reference. The Odyssey CLx Infrared Imaging System (LI-COR Biosciences, Lincoln, Nebraska, USA) was used for image capture and Image studio software was used to quantify bands in each group.

RNA extraction and RT-qPCR analysis

Total RNA extractions from mouse ventricular tissue and cultured primary cardiomyocytes were performed using Trizol™ Reagent (Invitrogen, USA) and measured on NanoDrop-2000 spectrophotometer. Reverse-cDNA synthesis was performed by ReverTra Ace qPCR RT Kit (TOYOBO, Japan) and SYBR Green PCR Master Mix (Dojima Hama, 2-Chome, Kita-ku Osako, Japan) was used for performing mRNA quantification. The real-time PCR was conducted using a selective adherent technique after digestion with 0.25% trypsin solution. Cardiomyocytes were cultured in DMEM with 10% fetal bovine serum, 1% penicillin and streptomycin in an atmosphere of 5% CO₂ and 95% air at 37 °C for 48 h. The Meis1 plasmid, negative control (NC) was synthesized by GenePharma (Shanghai, China), which were transiently transfected using Lipofectamine2000™ transfection reagent (Invitrogen, Carlsbad, CA, USA). After 24 h of transfection, the cells were moved to an anoxic area around the infarct of the pathological mouse heart as the peri-infarcted region. After quantification with the BCA Protein Assay kit (Shanghai, China), which were transiently transfected using Lipofectamine2000™ transfection reagent (Invitrogen, Carlsbad, CA, USA), 60 μg protein from each group was fractionated by 8% SDS-PAGE and electro-blotted onto NC membranes (Pall, New York, USA). Membranes were incubated with primary antibodies overnight at 4 °C, including rabbit anti-Meis1 antibody (Abcam, UK, Cat#: ab19867, 1:1000), rabbit anti-Nav1.5 antibody (Alomame laboratory, Israel, Cat#: ASC-005, 1:200), mouse anti-CDC20 antibody (Proteintech Group, America, Cat#: 10252-1-AP, 1:500), mouse anti-UB antibody (Santa Cruz Biotechnology, Europe, Cat#: sc-8017, 1:1000), mouse anti-His antibody (Santa Cruz Biotechnology, Europe, Cat#: sc-57598, 1:200) and mouse anti-flag antibody (Sigma, USA, Cat#: F1804, 1:1000). Mouse anti-β-Actin antibody (Zhongshanjinqiao, Beijing, China, Cat#: TA-09, 1:1000) was used as an internal reference. The Odyssey CLx Infrared Imaging System (LI-COR Biosciences, Lincoln, Nebraska, USA) was used for image capture and Image studio software was used to quantify bands in each group.

Immunofluorescence staining

Neonatal cardiomyocytes of each group were fixed in 4% paraformaldehyde (PFA) for 30 min at room temperature. After permeabilized with 0.5% Triton X-100 for 1 min and blocked with goat serum for 1 h, the samples were co-incubated with antibodies anti-Nav1.5 (Alomame laboratory, Israel, Cat#: ASC-005, 1:200) and anti-α-actinin (ab50599, Abcam, Cambridge, UK, 1:100) overnight at 4 °C. Then, cardiomyocytes were incubated with secondary antibody for 1 h at 37 °C in darkness, followed by nuclei staining of DAPI (Beyotime, Shanghai, China, 1:1000) for 10 min. A confocal laser scanning microscope (Zeiss, Oberkochen, Germany) was used to captured the immunofluorescence images.

Western blot analysis

Western blot was conducted to test the protein levels in mouse ventricular tissue and neonatal cardiomyocytes. We take the 2 mm area around the infarct of the pathological mouse heart as the peri-infarcted region. After quantification with the BCA Protein Assay kit (Shanghai, China), which were transiently transfected using Lipofectamine2000™ transfection reagent (Invitrogen, Carlsbad, CA, USA), 60 μg protein from each group was fractionated by 8% SDS-PAGE and electro-blotted onto NC membranes (Pall, New York, USA). Membranes were incubated with primary antibodies overnight at 4 °C, including rabbit anti-Meis1 antibody (Abcam, UK, Cat#: ab19867, 1:1000), rabbit anti-Nav1.5 antibody (Alomame laboratory, Israel, Cat#: ASC-005, 1:200), mouse anti-CDC20 antibody (Proteintech Group, America, Cat#: 10252-1-AP, 1:500), mouse anti-UB antibody (Santa Cruz Biotechnology, Europe, Cat#: sc-8017, 1:1000), mouse anti-His antibody (Santa Cruz Biotechnology, Europe, Cat#: sc-57598, 1:200) and mouse anti-flag antibody (Sigma, USA, Cat#: F1804, 1:1000). Mouse anti-β-Actin antibody (Zhongshanjinqiao, Beijing, China, Cat#: TA-09, 1:1000) was used as an internal reference. The Odyssey CLx Infrared Imaging System (LI-COR Biosciences, Lincoln, Nebraska, USA) was used for image capture and Image studio software was used to quantify bands in each group.

Statistical analysis

Data are presented as mean ± SEM. Two-tailed Student’s t-test was used to compare the differences between the two experimental groups and ANOVA was used to compare the difference among multiple groups. P value less than 0.05 was defined as statistical significance. All statistical analyses were carried out using GraphPad Prism 8.0 (GraphPad Software Inc., San Diego, CA).

Results

Meis1 is down-regulated in cardiomyocytes from the border zone of MI hearts

To assess the potential involvement of Meis1 in post-infarcted arrhythmias, the expression of Meis1 was firstly analyzed in MI mouse hearts and hypoxic cardiomyocytes. Compared with the sham group, the expression level of Meis1 was significantly decreased in the border zone of infarcted hearts (Fig. 1A). The reduction of Meis1 expression was also verified by immunohistochemistry of ventricular myocardium in infarcted mice (Fig. 1B). Consistent with the in vivo results, the protein level of Meis1 was decreased in the border zone of infarcted hearts

| Gene       | Forward primer                          | Reverse primer                          |
|------------|-----------------------------------------|-----------------------------------------|
| Meis1      | 5′-TCCAAAGATGCACCAAAATC-3′              | 5′-CTGTATCTGTCGCAACTGTTT-3′             |
| Na,1,5     | 5′-CAACGACAGAGGCGGAC-3′                 | 5′-GCTGCTCCCTATACCCCTCTG-3′             |
| CDC20      | 5′-CATCTACCTAACATCAAGGGC-3′             | 5′-ATGGAGGACACCTGGGAAT-3′               |
| GAPDH      | 5′-AGAAGGTGGTGTAAGCGAGGC-3′             | 5′-TCCACCAACCCATGGCTGTA-3′              |

Table 1. The primers sequences for real-time quantitative PCR.
down-regulated in neonatal mouse cardiomyocytes treated with hypoxia (Fig. 1C). In order to further verify whether Meis1 protein change is also present in human cardiomyocytes treated with hypoxia. We examined the Meis1 protein levels in human embryonic stem cells derived cardiomyocytes (hESC-CM) in each group. It was found that Meis1 also decreased in hypoxia-treated hESC-CM (Fig. 1D). The reduced expression of Meis1 in ischemic and hypoxic cardiomyocytes suggests that Meis1 might be involved in the pathological process of myocardial infarction.

**Forced overexpression of Meis1 inhibits the susceptibility of ventricular arrhythmias after MI**

Based on the above findings, we further explored whether the alteration of Meis1 is related to ischemic arrhythmias by the experimental procedure as shown in Fig. 2A. In vivo study, we constructed MI mouse model by the left anterior descending (LAD) coronary artery ligation, and then AAV9-cTNT-GFP (AAV9-NC) and AAV9-cTNT-GFP-Meis1 (AAV9-Meis1) were delivered into MI mouse models via tail vein injection. Four weeks after AAV9-Meis1 infection (1.3 × 10^{11} vg), the expression efficiency of Meis1 was verified by immunoblotting and GFP fluorescence intensity in various tissues. The results demonstrated that AAV9-Meis1 successfully induced the specific expression of Meis1 in mouse cardiomyocytes rather than other tissues, such as liver, kidney and spleen (Fig. 2B, Supplementary Fig. 1A). Furthermore, electrocardiogram investigation showed the prolongation of QRS complex in mice after MI (16.4 ± 0.2 ms in MI + AAV9-NC vs. 12.2 ± 0.4 ms in Sham, *P < 0.01*), which indicates the increased susceptibility of ventricular fibrillation and SCD in MI mice. Notably, the QRS prolongation induced by ischemic was markedly reversed in MI + AAV9-Meis1 group (from 16.4 ± 0.2 ms to 13.3 ± 0.4 ms, *P < 0.01*, Fig. 2C).

To further determine the role of Meis1 in the susceptibility of ischemic arrhythmias in mice with MI, we conducted the programmed ventricular stimulation induced representative ventricular fibrillation (VF). The susceptibility of arrhythmia was markedly

---

**Fig. 1.** Meis1 is down-regulated in ischemic cardiomyocytes. (A) The protein expression of Meis1 in the border zone of infracted hearts from Sham and MI mice (*n* = 6). (B) Immunohistochemical staining showed that the expression of Meis1 in ventricular myocardium of MI mice was decreased compared with the Sham group (*n* = 5). Scale bar, 20 μm. (C–D) The protein level of Meis1 in neonatal cardiomyocytes and human embryonic stem cells derived cardiomyocytes (hESC-CM) were reduced after treatment with hypoxia for 24 h compared with theCtl (*n* = 5–6). Two-tailed Student’s *t*-test was used to compare the differences between the two experimental groups. Error bars represent mean ± SEM. **P < 0.01.**
Fig. 2. Meis1 reduces the incidence of ventricular arrhythmias after myocardial infarction. (A) Schematic diagram of experimental procedure in vivo study. ES: electrical stimulation; ECG: electrocardiogram. (B) Compared with AAV9-NC, Meis1 protein level was increased in the hearts of mice in AAV9-Meis1 group, indicating that Meis1 overexpression in cardiomyocytes was successfully constructed (n = 3–5). (C) Representative ECG recorded from mice of each group (left panels). QRS complex was shortened in MI + AAV9-Meis1 group (from 16.4 ± 0.2 ms to 13.3 ± 0.4 ms) compared with MI + AAV9-NC mice (right panels, n = 6–8). (D) Representative ventricular fibrillation (upper tracing) and ECG (lower tracing) recorded by programmed ventricular stimulation (left panels). The incidence and duration of ventricular fibrillation in each group (right panels, n = 10). This stimulation procedure was repeated 3 times to ensure the reproducibility of the experiment, so as to assess the incidence of ventricular arrhythmia in mice after MI. RV EG: Right ventricular electrocardiogram. VF: ventricular fibrillation. One-way analysis was used to compare the difference among multiple groups. Error bars represent mean ± SEM. *P < 0.05, **P < 0.01.
elevated as demonstrated by the facilitated induction rate (70%) and extended duration of VF (35.7 ± 3.6 s vs. Sham) in infarcted mouse heart subjected to electrical stimuli. However, VF incidence was lower (from 70% to 30%) in MI + AAV9-Meis1 mice compared with MI + AAV9-NC group. Consistently, the overexpression of Meis1 in MI mice reduced the duration of ventricular fibrillation compared with AAV9-NC-treated MI mice (from 35.7 ± 3.6 s to 13.0 ± 4.7 s, P < 0.05, Fig. 2D). These results suggest that Meis1 overexpression inhibits the increased arrhythmic susceptibility in infarcted hearts.

Cardiac specific overexpression of Meis1 improves electrical conduction in mice after myocardial infarction

Abnormal cardiac conduction function is a significant feature of post-MI ventricular arrhythmias. To further characterize the epicardial conduction of the overexpressing Meis1 in the heart, electrophysiological assessment by optical mapping with a voltage-sensitive dye was performed in Langendorff-perfused mouse hearts. A representative activation map obtained by electrode pacing in each group was shown in Fig. 3A. Upon the stimulation with pacing cycle length at 200 ms, electrical conduction velocity (CV) of the ventricle were significantly slowed down in MI mice compared with the sham-operated group (0.29 ± 0.02 m/s vs.0.53 ± 0.03 m/s, P < 0.01), and this electrical conduction abnormality was attenuated from 0.29 ± 0.02 m/s to 0.45 ± 0.02 m/s in AAV9-Meis1 infected MI mice (Fig. 3B).

It is properly acknowledged that sodium current (I\textsubscript{Na}) is an established key factor for cardiac excitability and impulse propagation. Therefore, we speculated that the slowdown of cardiac conduction after myocardial infarction noticed in our study may be attributed to the damage of I\textsubscript{Na} currents. To investigate the effects of Meis1 on I\textsubscript{Na} currents, we first used conventional patch clamp techniques to study the I\textsubscript{Na} characteristics of isolated mouse ventricular myocytes. Representative whole-cell sodium current traces recorded from Sham, MI + AAV9-NC and MI + AAV9-Meis1 ventricular cells are showed in Fig. 3C. The current density was obtained via dividing the peak current by the capacitance of single cardiomyocyte. As illustrated in Fig. 3D, the current densities of I\textsubscript{Na} were obviously reduced in ischemic cardiomyocyte, in contrast to the density of myocardium in sham group mice. Interestingly, in the AAV9-Meis1 mice hearts, current recordings from −40 mV to −15 mV revealed a restoration in reduced I\textsubscript{Na} current density. At the test potential of −35 mV, the peak current density was −45.7 ± 0.6 pA/pF for Sham, −25.0 ± 2.3 pA/pF for MI + AAV9-NC and −35.8 ± 1.5 pA/pF for AAV9-Meis1. These data suggest that Meis1 overexpression is able to improve cardiac electrical conduction of MI hearts by recovering I\textsubscript{Na} currents and producing anti-arrhythmic effects. In addition, we also constructed the knockdown of Meis1 in mouse cardiomyocytes through AAV9 to further verify the regulation of Meis1 on sodium current. As expected, the average I\textsubscript{Na} densities, from test potentials of −50 mV to 0 mV, were significantly lower in AAV9-shMeis1 myocytes compared with AAV9-shNC group (−23.3 ± 2.5 pA/pF vs. −39.6 ± 1.7 pA/pF at −35 mV, P < 0.05, Fig. 3E,F).

Meis1 rescues the reduction of Na\textsubscript{v}1.5 channel in cardiomyocytes of MI mice

The above data indicates that Meis1 could prevent ischemic arrhythmias after MI by restoring cardiac conduction velocity. It has been demonstrated that the restraint or functional impairment of Na\textsubscript{v}1.5/SCN5A is the key inducement to slow down cardiac conduction in hearts [9,30]. Therefore, we further experimentally verify if Meis1 altered Na\textsubscript{v}1.5 expression in cardiomyocytes from the marginal area of the infarcted hearts. As illustrated in Fig. 4A and B, consistent with the changes of SCN5A mRNA, Na\textsubscript{v}1.5 protein expression was markedly down-regulated by approximately 50% in the hearts of MI group mice, which was attenuated significantly by AAV9-Meis1 administration in MI mouse hearts. This indicates that Meis1 prevents the decrease of I\textsubscript{Na} current in ischemic hearts by up-regulating the Na\textsubscript{v}1.5 protein level.

Furthermore, we also found that Meis1 increased the mRNA level of SCN5A in neonatal mouse cardiomyocytes exposed to hypoxia (Fig. 4C). Hypoxia treatment also significantly reduced the protein level of Na\textsubscript{v}1.5, which was attenuated by overexpression of Meis1 in hypoxic cardiomyocytes (Fig. 4D). Similarly, the Na\textsubscript{v}1.5 protein in the plasma membrane of neonatal mouse cardiomyocytes of the Hypoxia + Meis1 group was increased compared to the hypoxic cells observed by immunofluorescence technique (Fig. 4E).

The proximal promoter region of SCN5A DNA contains conserved Meis1 binding sites

The changes in mRNA and protein expression levels of the SCN5A gene in ischemic hearts indicates that transcription of SCN5A may be directly regulated by Meis1 in cardiomyocytes. Computational prediction of the high-quality and matrix-based transcription factor binding site profiles in the proximal region of the SCN5A promoter (2000 nt upstream) based on JASPAR database (JASPAR\textsuperscript{\textregistered}2020, http://jaspar.genereg.net/), in which includes seven highly conserved binding sites of Meis1, and chromatin immunoprecipitation (ChIP) assays were used to verify the predicted binding sites (Fig. 5A, B). As shown in Fig. 5B, the recruitment of Meis1 to the proximal promoter region of SCN5A DNA in mouse ventricular tissues, which was significantly reduced in MI group mice compared with sham-operated mice. With the effectively silencing and overexpressing of Meis1 in primary cultured neonatal cardiomyocytes by si-Meis1 and Meis1 plasmid transfection (Fig. 5C, D), the expression of Na\textsubscript{v}1.5 mRNA and protein was consistent with that of Meis1 (Fig. 5E, F). These results indicate that the transcription factor Meis1 has the potential to regulate transcriptional expression of SCN5A.

Hypoxia destabilizes Meis1 by promoting its ubiquitin proteasome dependent degradation

It was previously reported that the half-life of Meis1 was prolonged and blocked from entering ubiquitin proteasome-mediated degradation in leukemia model [31]. Nevertheless, there is little evidence indicating whether Meis1 might be dysregulated through ubiquitination pathways in cardiomyocytes. To understand the underlying mechanisms leading to the prompt degrada-

dtion of Meis1 after hypoxia, we firstly examined the stability of Meis1 protein in normoxic and hypoxic condition. Indeed, after the protein was inhibited by cycloheximide (CHX), the half-life of Meis1 protein in hypoxic cardiomyocytes than in normoxic condition. Importantly, the effect of hypoxia on Meis1 was restrained in the presence of the proteasome inhibitor MG132 in cardiomyocytes (Fig. 6B). Subsequently, the ubiquitination status of Meis1 in cardiomyocytes upon hypoxia treatment was analyzed through co-immunoprecipitation, which confirmed that the ubiquitination level was extensively enhanced in comparison with the control group (Fig. 6C). These findings indicate that the ubiquitin proteasome pathway is involved in the hypoxia mediated down-regulation of Meis1.
Effect of Meis1 on cardiac electrical conduction in mouse hearts with MI. (A) Representative image of epicardial conduction recorded by optical mapping in Sham, MI + AAV9-NC and MI + AAV9-Meis1 group. The color bar indicates the activation time in milliseconds (ms). The arrows represent the electrode stimulation position. (B) Statistical data of conduction velocity in mouse hearts (n = 6–7). The data showed that cardiac conduction was slowed down in mice with MI, which was reversed by the overexpression of Meis1, **P < 0.01. (C) Representative whole cell I_Na traces were recorded at the potentials between −90 mV and +25 mV from a holding potential of −100 mV in the left ventricular myocytes isolated from Sham, MI + AAV9-NC and MI + AAV9-Meis1 group. (D) The current-density-voltage relationship curves of I_Na indicated that the current densities were obviously reduced in MI + AAV9-NC group, which were restored in the AAV9-Meis1 mice hearts at the potential of −40 mV to −15 mV. *P < 0.05 vs. Sham group; #P < 0.05 vs. MI + AAV9-NC group, n = 5 mice. (E-F) The average sodium current densities were significantly lower in AAV9-shMeis1 myocytes compared with AAV9-shNC group at −50 mV to 0 mV, Two-tailed Student’s t-test was used to compare the differences between the two experimental groups, mean ± SEM, *P < 0.05, n = 6 mice.
**CDC20 promotes Meis1 ubiquitination and degradation in cardiomyocytes**

The ubiquitin-proteasome system is essential for protein homeostasis. The interaction between E3 ubiquitin ligase and the target protein is a core step of protein degradation mediated by the ubiquitin-proteasome system [32]. E3 ubiquitin ligase mediates the destruction of homologous substrates by adding ubiquitin to the lysine residues of the substrates. Therefore, we firstly used Ubi-Browser database (http://ubibrowser.ncpsb.org/) and real-time PCR assay to identify the potential E3 ubiquitin ligases interacting with Meis1. As shown in **Fig. 7A**, compared with other ligases, CDC20 mRNA expression was found markedly up-regulated in MI mouse hearts. Moreover, CDC20 protein levels were also increased in both MI mouse hearts and neonatal mouse cardiomyocytes after exposure to hypoxia (**Fig. 7B, C**). Since the expression of CDC20 is up-regulated in ischemic and hypoxic cardiomyocytes, we speculated that CDC20 may be the key E3 enzyme of Meis1 to regulate its ubiquitin-proteasome degradation. Firstly, we evaluated whether CDC20 is responsible for Meis1 protein degradation in ischemic cardiomyocytes. Compared with the si-NC group, knockdown of CDC20 in cardiomyocytes via siRNA appreciably enhanced Meis1 and NaV1.5 protein levels after 24 h of hypoxia treatment (**Fig. 7D**). Conversely, overexpression of CDC20 reduced the level

---

**Fig. 4.** Meis1 inhibits the down-regulation of SCN5A/NaV1.5 expression in MI hearts and hypoxic cardiomyocytes. (A-B) The mRNA and protein expression of sodium channel subunit SCN5A/NaV1.5 in the border zone of infracted hearts from Sham, MI + AAV9-NC and MI + AAV9-Meis1 group (n = 6). (C-D) The expression of SCN5A/NaV1.5 at mRNA and protein level in neonatal mouse cardiomyocytes after treatment with hypoxia for 24 h with or without forced expression of Meis1 (n = 6). (E) Immunofluorescence staining for NaV1.5 (green), α-actinin (red) proteins in neonatal mouse cardiomyocytes after treatment with hypoxia for 24 h with or without overexpression of Meis1 (left panels) and enlargement of outlined squares (right panels). Scale bar indicates 5 μm/2 μm. One-way ANOVA was used to determine statistical significance in these experiments. Error bars represent mean ± SEM of each group. *P < 0.05, **P < 0.01. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
of Meis1 and Na\textsubscript{v}1.5 protein compared with the hypoxia alone treatment group (Fig. 7E). These results suggest that CDC20 is involved in regulation of Meis1 stability in hypoxic cardiomyocytes.

**CDC20 involves the protective effect of Meis1 on ischemic-induced Na\textsubscript{v}1.5 reduction**

Moreover, after co-transfected with Flag-Meis1 and His-CDC20 plasmids in HEK293T cells for 48 h, we found that Meis1 could be detected upon CDC20 pull down by co-immunoprecipitation assay (Fig. 8A). The result of pull-down assay indicated that a physical interaction between Meis1 and CDC20 in cardiomyocytes. Moreover, after co-transfected with Flag-Meis1 and His-CDC20 plasmids in HEK293T cells for 48 h, we found that Meis1 could be detected upon CDC20 pull down by co-immunoprecipitation assay (Fig. 8A). The result of pull-down assay indicated that a physical interaction between Meis1 and CDC20 in cardiomyocytes. Moreover, the endogenous CDC20 protein could be effectively precipitated by anti-Meis1 antibody (Fig. 8B). To determine whether CDC20 reduced the stability of Meis1 through the ubiquitin proteasome pathway, IP technique was performed with Meis1 antibody in neonatal mouse cardiomyocytes. The results showed that overexpression of CDC20 significantly enhanced the ubiquitination level and degradation of Meis1 (Fig. 8C). On the contrary, silencing of CDC20 reduced Meis1 ubiquitination and degradation compared with the si-NC group (Fig. 8D). These results indicate that CDC20 regulates ubiquitination of Meis1 directly. Furthermore, we also
founded that the effect of CDC20 on the degradation of Meis1 was abolished in the presence of the proteasome inhibitor MG132 in cardiomyocytes (Fig. 8E). Knockdown of CDC20 by si-CDC20 increased the protein level of Meis1 compared with the si-NC treatment cells, and which is more evident after treatment with MG132 in neonatal cardiomyocytes (Fig. 8F). Overall, these results suggest that CDC20 regulates Meis1 protein levels in a ubiquitin-proteasome-dependent manner.

Next, we further explored whether CDC20 affected the expression of NaV1.5 by regulating Meis1. Immunoblotting assays confirmed that the NaV1.5 protein expression was increased when CDC20 was knocked down in neonatal cardiomyocytes after hypoxia treatment, which was markedly reversed by siRNA-Meis1 (Fig. 8G). It suggests that CDC20 mediates the protective effect of Meis1 on ischemic-induced NaV1.5 reduction.

Discussion

Fatal arrhythmias and subsequent sudden cardiac death are the most frequent causes of death in patients with MI [33–34]. The imbalance of cardiac ion channels expression and function results in myocardial electrical remodeling after MI. For the first time, we uncovered that the up-regulation of CDC20 in ischemic cardiomyocytes after MI leads to the accelerated degradation of Meis1 in the manner of ubiquitin–proteasome system, which leads to the dysfunction of cardiac Na⁺ channel (SCN5A/NaV1.5) and then ultimately induces an increased susceptibility to arrhythmias. The finding provides novel insights into the mechanisms of ventricular arrhythmias after MI, and confers Meis1 as a new therapeutic target for sudden cardiac death.

Meis1, as a three-amino-acid loop extension (TALE) family homeobox gene, plays an important role in leukemia, tumor and cardiac regeneration [35]. It has been reported that Meis1 inactivation in mouse neurons induces the dysfunction of sympathetic and vagal regulation of cardiac rhythmicity and cardiac conduction defects, thus increasing the susceptibility to SCD [17]. Although inactivation of Meis1 has been shown to cause neurological disorders, the functions of Meis1 in the development of ventricular arrhythmias after myocardial infarction has not been reported. Here, we found that the forced expression of Meis1 could inhibit the incidence of arrhythmias and restore cardiac conduction velocity in MI mice. It suggests that Meis1 might be a new target for the treatment of arrhythmias after MI.
It has been widely accepted that abnormal Na+ channel affects electrical conduction and cardiac excitability, which is associated with cardiac arrhythmias after myocardial infarction, such as serious ventricular arrhythmias and LQT syndrome [36–37]. The incidence of ventricular arrhythmia in patients with loss of function of sodium channel is much higher than that in healthy individuals [38]. Consistent with previous studies, we found that the prolongation of QRS complex in MI mice was accompanied by a decrease in...
the expression of Na\textsubscript{v}1.5, α subunit of the cardiac Na\textsuperscript{+} channel in the marginal zone of myocardial infarction in mice. However, the mechanism underlying cardiac sodium channel dysfunction in MI, especially at the transcriptional aspect, is not yet clear. Interestingly, our study showed that there are multiple binding sites between Meis1 and the promoter region of SCN5A DNA, and the overexpression of Meis1 could restore the reduction of Na\textsubscript{v}1.5 in cardiomyocytes and reverse the QRS prolongation. Surprisingly,
we found that Meis1 could also restore the QTc (heart rate corrected QT) interval of the infarcted heart, indicating that Meis1 might also participate in the repolarization process of the heart. Potassium current (I\textsubscript{K}) and calcium current (I\textsubscript{Ca}) cooperate with I\textsubscript{Na} to mediate the process of orderly electrical activity of the heart. Here we firstly revealed the transcriptional regulation mechanism of sodium channel (SCN5A/Na\textsubscript{v1.5}) mediated by Meis1 during myocardial infarction. However, we cannot exclude a potential contribution of Meis1 function on other ion channels which should be defined in future studies. In addition, the electrical conduction of the heart is affected by both intracellular conduction and intercellular communication. Connexin43 (Cx43), has been identified as essential for the cell-to-cell transmission of action potential in cardiomyocytes, which co-determines cardiac depolarization with sodium channel activation [39]. Here, we also observed the effects of Meis1 on Connexin43 in the hearts of each group mice. However, the results displayed that the overexpression of Meis1 could not restore the downregulation of Connexin43 protein in infarcted hearts (Supplementary Fig. 2A). This suggested that the effect of Meis1 on cardiac conduction might be more specific to sodium currents rather than the cardiac gap junction.

Meis1 has been showed to be involved in the vascularization of ischemic myocardial tissue and inhibit angiotensin II-induced myocardial hypertrophy by promoting the expression of Poly (rC)-binding protein 2 [40]. Fabrice et al. also reported that the loss of transcription factor Meis1 increases the sensitivity to sudden cardiac death by inhibiting the sympathetic neurons target-field innervation [17]. In this study, we demonstrated that the downregulation of Meis1 in cardiomyocytes reduced the transcriptional regulation of SCN5A, which eventually lead to the increased susceptibility of arrhythmias in mice after MI.

However, the mechanism leading to the down regulation of Meis1 in this pathological process still undefined. In the current study, we discovered that the degradation of Meis1 protein was accelerated in MI mouse hearts and hypoxic cardiomyocytes by the ubiquitin proteasome pathway. Previous studies have found that E3 ubiquitin ligase CDC20 significantly increased K48-linked ubiquitination level and Meis1 degradation in leukemia models [26]. Increasing evidence indicates that CDC20 binds directly to LC3 and promotes the ubiquitination and degradation of LC3 through proteasome, thus inhibiting cardiac autophagy and hypertrophy [41]. However, whether CDC20 regulates the proteasomal degradation of Meis1 in ischemic cardiomyocytes is unknown. Here, we found that the expression of CDC20 was up-regulated in the border zone of infarcted hearts and hypoxic cardiomyocytes. After hypoxia stimulation, knockdown of CDC20 in cardiomyocytes restored the expression of Na\textsubscript{v1.5} and Meis1, but overexpression of CDC20 exacerbated their down-regulation, demonstrating that CDC20 exerts an important regulatory effect on sodium channel (Na\textsubscript{v1.5}) and Meis1 in cardiomyocytes.

We then further investigated whether Meis1 degraded through the ubiquitination regulation of CDC20. In this study, we revealed for the first time the binding relationship between Meis1 and CDC20 in cardiomyocytes of MI mice. At the same time, it was found that Meis1 did degrade through the ubiquitination of CDC20 under the stimulation of hypoxia, and thus failed to exert the regulation of Na\textsubscript{v1.5}. Our findings furnish original mechanistic insights into the probably links amongst CDC20 and Meis1 regulating Na\textsubscript{v1.5} in cardiomyocytes.

Conclusions

In summary, the present study is the first to investigate the regulatory effect of Meis1 on arrhythmia in adult mice with myocardial infarction. The expression of Meis1 was down-regulated in ischemic cardiomyocytes, which may be mainly caused by CDC20-mediated ubiquitination. After the Meis1 level was restored, the electrophysiological function in marginal zone of infarcted mouse hearts and I\textsubscript{Na}\textsubscript{v} current density in cardiomyocytes were significantly improved. It provides strong evidences that Meis1 has the anti-arrhythmic effects by mediating SCN5A in the process of myocardial infarction. These findings confer novel therapeutic strategies for MI complicated with malignant arrhythmias and sudden cardiac death.

Compliance with Ethics Requirements

This research has fully complied with research ethics. All animal experiments were performed along with the NIH guidelines (Guide for the care and use of laboratory animals, NIH Publication No. 85-23, revised 1996) and the ARRIVE guidelines. All experiments were conducted in accordance with the protocols approved by the Institutional Animal Care and Use Committee of Harbin Medical University.

CRediT authorship contribution statement

Yining Liu: Writing – original draft, Investigation, Validation, Visualization, Methodology, Formal analysis. Jimin Li: Methodology, Conceptualization. Ning Xu: Methodology, Investigation, Validation. Hang Yu: Validation, Investigation. Liling Gong: Investigation, Formal analysis. Qingsui Li: Investigation, Data curation. Zhenyu Yang: Methodology, Investigation, Validation. Sijia Li: Investigation, Formal analysis. Jiming Yang: Investigation, Validation. Di Huang: Formal analysis. Yadong Xue: Investigation, Validation. Genlong Xue: Investigation, Validation. Jiali Liu: Investigation. Haixin Chen: Methodology, Investigation. Ruijie Zhang: Formal analysis. Anqi Li: Methodology, Investigation. Yiming Zhao: Investigation. Pengyu Li: Data curation. Ming Li: Methodology. Mingbin Liu: Validation, Formal analysis. Benzhi Cai: Conceptualization, Writing – original draft. Ning Wang: Visualization, Writing – original draft, Conceptualization, Supervision, Project administration.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work was supported by Heilongjiang Touyan Innovation Team Program [NW, BZC]; HMU Marshal Initiative Funding [Grant No. HMUMIF-21026 to NW]; the National Nature Science Foundation of China [Grant No. 82170284 and 81773733 to NW]; National Nature Science Youth Foundation of China [Grant No. 82003751 to JML]; Foundation of Heilongjiang postdoctoral [LBH-Z18166 to JML] and Outstanding Youth Fostering Foundation of Vihan Academician [NW]. The mechanism diagram was created with BioRender.com.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jare.2021.11.004.

References

[1] Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnizky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69(2):250–8.

288
[2] Aimond F, Alvarez JL, Rauzier JM, Lorente P, Vassort G. Ionic basis of ventricular arrhythmias in remodeled rat heart during long-term myocardial infarction. Cardiovasc Res 1999;42(2):402–15.

[3] Baya MR, Leroux RG, Dorian P, Rea TD, Newgard CD, Morrison LJ, et al. Survival After Intraaortic Versus Intraaortic Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refactory Cardiac Arrest. Circulation 2020;141(3):188–98.

[4] Shy D, Gillet I, Abriel H. Cardiac sodium channel NaV1.5 distribution in myocytes via interacting proteins: the multiple pool model. Biochim Biophys Acta 2013;1833(4):886–94.

[5] Liu M, Yang KC, Dudley JR SC. Cardiac Sodium Channel Mutations: Why so Many Phenotypes? Curr Top Membr 2016;78:513–59.

[6] Wagner S, Maier LS, Berg DM. Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death. Circ Res 2015;116(12):1956–70.

[7] Pu J, Boyden PA. Alterations of Na+ currents in myocytes from epicardial border zone of the infarcted heart. A possible ionic mechanism for reduced excitability and postrepolarization refractoriness. Circ Res 1997;81(1):110–9.

[8] Baba S, Dun W, Cabo C, Boyden PA. Remodeling in cells from different regions of the reentrant circuit during ventricular tachycardia. Circulation 2005;112(16):2386–96.

[9] Li J, Xu C, Liu Y, Li Y, Du S, Zhang R, et al. Fibroblast growth factor 21 inhibited ischemic arrhythmias via targeting miR-143/145 axis. Basic Res Cardiol 2020;115(2). doi: https://doi.org/10.1007/s00395-019-0768-4.

[10] Shang LL, Pfahnl AE, Sanyis Z, Jiao Z, Allen J, Banach K, et al. Human heart failure is associated with abnormal C-terminal splicing variants in the cardiac sodium channel. Circ Res 2007;101(1):1146–54.

[11] Voerman CC, Wilde AAM, Lodder EM. The cardiac sodium channel gene SCN5A and its gene product NaV1.5: Role in physiology and pathophysiology. Gene 2015;573(2):177–87.

[12] Roychoudhury J, Clark JP, Gracia-Maldonado G, Unnisa Z, Wunderlich M, Link JT, et al. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 2018;114(5):724-36.

[13] Solomon SD, Zelenkofske S, Finn PV, Velazquez E, Erti G, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352(25):2581–8.

[14] Soliman EZ, Musani SK, et al. Novel interventricular differences in tissue architecture underlie right ventricular susceptibility to conduction abnormalities in a mouse model of Brugada syndrome. Cardiovasc Res 2018;114(5):724-36.

[15] Smith JG, Magnani JW, Palmer C, Meng YA, Musani SK, et al. Many Phenotypes? Curr Top Membr 2016;78:513–59.